Does the media prefer SGHT or INSP?

In the previous week, Sight Sciences had 5 more articles in the media than Inspire Medical Systems. MarketBeat recorded 14 mentions for Sight Sciences and 9 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 1.24 beat Sight Sciences' score of 0.39 indicating that Inspire Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inspire Medical Systems 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SGHT or ESTA?

In the previous week, Sight Sciences had 8 more articles in the media than Establishment Labs. MarketBeat recorded 14 mentions for Sight Sciences and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.87 beat Sight Sciences' score of 0.39 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Establishment Labs 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SGHT or LMAT?

In the previous week, Sight Sciences had 11 more articles in the media than LeMaitre Vascular. MarketBeat recorded 14 mentions for Sight Sciences and 3 mentions for LeMaitre Vascular. Sight Sciences' average media sentiment score of 0.39 beat LeMaitre Vascular's score of 0.00 indicating that Sight Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LeMaitre Vascular 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SGHT or NVCR more profitable?

NovoCure has a net margin of -21.25% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -35.69% -43.39% -22.86% NovoCure -21.25% -44.00% -15.85%

Does the media prefer KMTS or SGHT?

In the previous week, Sight Sciences had 12 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 14 mentions for Sight Sciences and 2 mentions for Kestra Medical Technologies. Kestra Medical Technologies' average media sentiment score of 0.54 beat Sight Sciences' score of 0.39 indicating that Kestra Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sight Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sight Sciences (SGHT) Competitors

$8.89 +0.42 (+4.96%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.88 -0.01 (-0.11%)

As of 10/9/2026 07:30 PM Eastern

Compare

SGHT vs. INSP, ESTA, LMAT, NVCR, and KMTS

Should you buy Sight Sciences stock or one of its competitors? Sight Sciences's main competitors and comparable companies include Inspire Medical Systems (INSP), Establishment Labs (ESTA), LeMaitre Vascular (LMAT), NovoCure (NVCR), and Kestra Medical Technologies (KMTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Sight Sciences compare to Inspire Medical Systems?

Sight Sciences (NASDAQ:SGHT) and Inspire Medical Systems (NYSE:INSP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Sight Sciences has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 30.4% of Sight Sciences shares are held by company insiders. Comparatively, 2.2% of Inspire Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Inspire Medical Systems has a net margin of 15.03% compared to Sight Sciences' net margin of -35.69%. Inspire Medical Systems' return on equity of 8.64% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-35.69%	-43.39%	-22.86%
Inspire Medical Systems	15.03%	8.64%	7.45%

Sight Sciences currently has a consensus target price of $8.38, suggesting a potential downside of 5.79%. Inspire Medical Systems has a consensus target price of $67.29, suggesting a potential downside of 2.33%. Given Inspire Medical Systems' higher possible upside, analysts clearly believe Inspire Medical Systems is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inspire Medical Systems	4 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.05

Inspire Medical Systems has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	6.33	-$38.43M	-$0.56	N/A
Inspire Medical Systems	$911.98M	2.18	$145.42M	$4.62	14.91

In the previous week, Sight Sciences had 5 more articles in the media than Inspire Medical Systems. MarketBeat recorded 14 mentions for Sight Sciences and 9 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 1.24 beat Sight Sciences' score of 0.39 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspire Medical Systems	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inspire Medical Systems beats Sight Sciences on 11 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to Establishment Labs?

Sight Sciences (NASDAQ:SGHT) and Establishment Labs (NASDAQ:ESTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Sight Sciences has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Sight Sciences has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	6.33	-$38.43M	-$0.56	N/A
Establishment Labs	$211.08M	8.71	-$51.06M	-$1.31	N/A

Sight Sciences currently has a consensus price target of $8.38, suggesting a potential downside of 5.79%. Establishment Labs has a consensus price target of $100.25, suggesting a potential upside of 62.56%. Given Establishment Labs' stronger consensus rating and higher probable upside, analysts clearly believe Establishment Labs is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Establishment Labs has a net margin of -15.82% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-35.69%	-43.39%	-22.86%
Establishment Labs	-15.82%	-196.69%	-10.73%

In the previous week, Sight Sciences had 8 more articles in the media than Establishment Labs. MarketBeat recorded 14 mentions for Sight Sciences and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.87 beat Sight Sciences' score of 0.39 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Establishment Labs	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Establishment Labs beats Sight Sciences on 9 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to LeMaitre Vascular?

Sight Sciences (NASDAQ:SGHT) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, Sight Sciences had 11 more articles in the media than LeMaitre Vascular. MarketBeat recorded 14 mentions for Sight Sciences and 3 mentions for LeMaitre Vascular. Sight Sciences' average media sentiment score of 0.39 beat LeMaitre Vascular's score of 0.00 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 30.4% of Sight Sciences shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sight Sciences has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Sight Sciences currently has a consensus price target of $8.38, indicating a potential downside of 5.79%. LeMaitre Vascular has a consensus price target of $110.60, indicating a potential upside of 37.07%. Given LeMaitre Vascular's higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
LeMaitre Vascular	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

LeMaitre Vascular has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	6.33	-$38.43M	-$0.56	N/A
LeMaitre Vascular	$262.43M	7.03	$57.73M	$2.85	28.31

LeMaitre Vascular has a net margin of 25.02% compared to Sight Sciences' net margin of -35.69%. LeMaitre Vascular's return on equity of 15.63% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-35.69%	-43.39%	-22.86%
LeMaitre Vascular	25.02%	15.63%	10.06%

Summary

LeMaitre Vascular beats Sight Sciences on 10 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to NovoCure?

Sight Sciences (NASDAQ:SGHT) and NovoCure (NASDAQ:NVCR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

NovoCure has a net margin of -21.25% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-35.69%	-43.39%	-22.86%
NovoCure	-21.25%	-44.00%	-15.85%

In the previous week, Sight Sciences had 13 more articles in the media than NovoCure. MarketBeat recorded 14 mentions for Sight Sciences and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.86 beat Sight Sciences' score of 0.39 indicating that NovoCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Sight Sciences	Neutral
NovoCure	Positive

Sight Sciences has higher earnings, but lower revenue than NovoCure. Sight Sciences is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	6.33	-$38.43M	-$0.56	N/A
NovoCure	$655.35M	2.59	-$136.23M	-$1.30	N/A

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 30.4% of Sight Sciences shares are held by company insiders. Comparatively, 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sight Sciences has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

Sight Sciences presently has a consensus price target of $8.38, suggesting a potential downside of 5.79%. NovoCure has a consensus price target of $21.20, suggesting a potential upside of 45.40%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Sight Sciences beats NovoCure on 9 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Kestra Medical Technologies has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market.

Kestra Medical Technologies currently has a consensus target price of $28.38, indicating a potential upside of 5.17%. Sight Sciences has a consensus target price of $8.38, indicating a potential downside of 5.79%. Given Kestra Medical Technologies' higher possible upside, equities research analysts plainly believe Kestra Medical Technologies is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sight Sciences has a net margin of -35.69% compared to Kestra Medical Technologies' net margin of -140.43%. Sight Sciences' return on equity of -43.39% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-140.43%	-63.83%	-44.76%
Sight Sciences	-35.69%	-43.39%	-22.86%

In the previous week, Sight Sciences had 12 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 14 mentions for Sight Sciences and 2 mentions for Kestra Medical Technologies. Kestra Medical Technologies' average media sentiment score of 0.54 beat Sight Sciences' score of 0.39 indicating that Kestra Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sight Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.5% of Sight Sciences shares are held by institutional investors. 5.3% of Kestra Medical Technologies shares are held by company insiders. Comparatively, 30.4% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sight Sciences has lower revenue, but higher earnings than Kestra Medical Technologies. Sight Sciences is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$106.73M	15.06	-$131.61M	-$2.67	N/A
Sight Sciences	$77.36M	6.33	-$38.43M	-$0.56	N/A

Summary

Sight Sciences beats Kestra Medical Technologies on 11 of the 16 factors compared between the two stocks.

Get Sight Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGHT vs. The Competition

Export

Metric	Sight Sciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$466.60M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-15.88	25.57	274.15	26.16
Price / Sales	6.33	83.27	590.48	94.54
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	7.35	5.93	11.21	6.34
Net Income	-$38.43M	$146.18M	$3.50B	$381.90M
7 Day Performance	4.22%	-0.38%	-0.90%	-1.41%
1 Month Performance	10.99%	-2.02%	-4.44%	-3.48%
1 Year Performance	177.81%	5.08%	6.96%	1.16%

Sight Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGHT Sight Sciences	1.4426 of 5 stars	$8.89 +5.0%	$8.38 -5.8%	+163.0%	$466.60M	$77.36M	N/A	186	Gap Up
INSP Inspire Medical Systems	2.8083 of 5 stars	$72.76 +3.9%	$66.50 -8.6%	-14.1%	$2.02B	$898.74M	15.75	1,333	Positive News Analyst Upgrade
ESTA Establishment Labs	3.3316 of 5 stars	$63.70 -2.5%	$100.25 +57.4%	+53.7%	$1.95B	$211.08M	N/A	1,004
LMAT LeMaitre Vascular	4.0184 of 5 stars	$82.89 +0.7%	$110.60 +33.4%	-7.6%	$1.88B	$249.60M	29.08	655	Analyst Upgrade
NVCR NovoCure	3.0251 of 5 stars	$15.99 +1.0%	$21.20 +32.6%	+1.7%	$1.84B	$699.19M	N/A	1,605	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGHT) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sight Sciences (SGHT) Competitors

SGHT vs. INSP, ESTA, LMAT, NVCR, and KMTS

How does Sight Sciences compare to Inspire Medical Systems?

Summary

How does Sight Sciences compare to Establishment Labs?

Summary

How does Sight Sciences compare to LeMaitre Vascular?

Summary

How does Sight Sciences compare to NovoCure?

Summary

How does Sight Sciences compare to Kestra Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sight Sciences (SGHT) Competitors

SGHT vs. INSP, ESTA, LMAT, NVCR, and KMTS

How does Sight Sciences compare to Inspire Medical Systems?

Which has more risk & volatility, SGHT or INSP?

Do institutionals and insiders believe in SGHT or INSP?

Is SGHT or INSP more profitable?

Do analysts rate SGHT or INSP?

Which has stronger valuation & earnings, SGHT or INSP?

Does the media prefer SGHT or INSP?

Summary

How does Sight Sciences compare to Establishment Labs?

Which has more risk & volatility, SGHT or ESTA?

Which has stronger earnings & valuation, SGHT or ESTA?

Do analysts recommend SGHT or ESTA?

Is SGHT or ESTA more profitable?

Does the media refer more to SGHT or ESTA?

Do institutionals & insiders hold more shares of SGHT or ESTA?

Summary

How does Sight Sciences compare to LeMaitre Vascular?

Does the media refer more to SGHT or LMAT?

Do institutionals and insiders believe in SGHT or LMAT?

Which has more risk & volatility, SGHT or LMAT?

Do analysts rate SGHT or LMAT?

Which has better valuation & earnings, SGHT or LMAT?

Is SGHT or LMAT more profitable?

Summary

How does Sight Sciences compare to NovoCure?

Is SGHT or NVCR more profitable?

Does the media refer more to SGHT or NVCR?

Which has stronger valuation & earnings, SGHT or NVCR?

Do institutionals & insiders hold more shares of SGHT or NVCR?

Which has more volatility and risk, SGHT or NVCR?

Do analysts prefer SGHT or NVCR?

Summary

How does Sight Sciences compare to Kestra Medical Technologies?

Which has more volatility and risk, KMTS or SGHT?

Do analysts recommend KMTS or SGHT?

Is KMTS or SGHT more profitable?

Does the media prefer KMTS or SGHT?

Do institutionals and insiders have more ownership in KMTS or SGHT?

Which has preferable valuation and earnings, KMTS or SGHT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools